Sarah Zuerndorfer

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

Stephen L. Sazinsky, Kutlu G. Elpek, M. Gostissa, 2020, PloS one.

Persistent antigen exposure via the eryptotic pathway drives terminal T cell dysfunction

J. Hubbell, J. Roberts, A. Dunaif, 2021, Science Immunology.